The development and appraisal of a tool designed to find patients harmed by falsely labelled, falsified (counterfeit) medicines. by Anđelković, Marija et al.
RESEARCH ARTICLE Open Access
The development and appraisal of a tool
designed to find patients harmed by falsely
labelled, falsified (counterfeit) medicines
Marija Anđelković1, Einar Björnsson2, Virgilio De Bono3, Nenad Dikić1, Katleen Devue4, Daniel Ferlin5,
Miroslav Hanževački6, Freyja Jónsdóttir2, Mkrtich Shakaryan7 and Sabine Walser8*
Abstract
Background: Falsely labelled, falsified (counterfeit) medicines (FFCm’s) are produced or distributed illegally and can
harm patients. Although the occurrence of FFCm’s is increasing in Europe, harm is rarely reported. The European
Directorate for the Quality of Medicines & Health-Care (EDQM) has therefore coordinated the development and
validation of a screening tool.
Methods: The tool consists of a questionnaire referring to a watch-list of FFCm’s identified in Europe, including
symptoms of their use and individual risk factors, and a scoring form. To refine the questionnaire and reference
method, a pilot-study was performed in 105 self-reported users of watch-list medicines. Subsequently, the tool was
validated under “real-life conditions” in 371 patients in 5 ambulatory and in-patient care sites (“sub-studies”). The
physicians participating in the study scored the patients and classified their risk of harm as “unlikely” or “probable”
(cut-off level: presence of ≥2 of 5 risk factors). They assessed all medical records retrospectively (independent
reference method) to validate the risk classification and documented their perception of the tool’s value.
Results: In 3 ambulatory care sites (180 patients), the tool correctly classified 5 patients as harmed by FFCm’s. The
positive and negative likelihood ratios (LR+/LR-) and the discrimination power were calculated for two cut-off levels:
a) 1 site (50 patients): presence of two risk factors (at 10% estimated health care system contamination with
FFCm’s): LR + 4.9/LR-0, post-test probability: 35%;
b) 2 sites (130 patients): presence of three risk factors (at 5% estimated prevalence of use of non-prescribed
medicines (FFCm’s) by certain risk groups): LR + 9.7/LR-0, post-test probability: 33%.
In 2 in-patient care sites (191 patients), no patient was confirmed as harmed by FFCm’s.
The physicians perceived the tool as valuable for finding harm, and as an information source regarding risk factors.
Conclusions: This “decision aid” is a systematic tool which helps find in medical practice patients harmed by
FFCm’s. This study supports its value in ambulatory care in regions with health care system contamination and in
certain risk groups.
The establishment of systematic communication between authorities and the medical community concerning
FFCm’s, current patterns of use and case reports may sustain positive public health impacts.
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Background
Falsely labelled, falsified (counterfeit) medicines (FFCm’s)
pose a health risk: they often do not contain the correct in-
gredients (or those labelled), may have been trafficked by
criminals and may have been contaminated with toxic sub-
stances during non-regulated production and distribution.
The occurrence of FFCm’s is increasing everywhere,
including in Europe [1–8]. Although attempts at re-
moval from the market remain incomplete [9, 10], health
damage in Europe is not visible in health statistics: this
may be explained in part by a lack of specific vigilance
and awareness as well as under-reporting.
The early detection of signs and symptoms of health
damage caused by FFCm’s can support decision- making
on treatment, but is at present hampered by the unavail-
ability of validated screening tools.
A screening tool needs to consider the main factors in-
fluencing the extent of health damage caused by FFCm’s
in an individual, such as the types and quality of defects
of circulating FFCm’s and/or patterns of their use.
Methods
Study aim
The aim was firstly to develop and validate a tool which
can support physicians to find patients harmed by
FFCm’s and secondly to assess the added value of the
tool to physicians.
Study design
The study was observational. It did not require diagnos-
tic tests or therapies in addition to those which would
have been carried out by the health care site to treat the
patient. The design took the following circumstances
into account under which the tool would be used: health
care system contamination with FFCm’s and/or pur-
chases of medicines/health care products by individuals
from uncontrolled outlets.
Development of the tool
A preliminary concept for an “anamnesis” form for clin-
ical use was produced by experts in the framework of a
specific work program coordinated by the EDQM,
Council of Europe.1 The concept was mentioned in a
preliminary report [11]. Based on this concept, we
further developed the tool and designed the study
approach, regularly consulting with the above experts as
well as with those from the national official medicines
control laboratories (OMCL). These laboratories carry
out market surveillance programmes in Europe, and can
thus be used as a reference for the quality of medicines
including issues with substandard and FFCm’s [12].2
The tool was designed to complement usual diagnosis
and treatment-planning processes during consultation: it
consisted of 1) a questionnaire, 2) a watch-list of FFCm’s
identified in Europe, relevant patterns of their use (“life-
styles”) and clinical signs and symptoms and 3) a scoring
form (See “Tool: Questionnaire and scoring form” in
Additional file 1. The watch-list is available upon request
from the EDQM contact person. See “Data and
Materials”).
The following 5 domains are included in the
questionnaire:
 health complaints;
 medical history;
 use of medicines;
 use of health care products;
 life-styles relevant for exposure to FFCm’s.
The scoring form comprised these 5 domains which con-
tributed equally (20 scores each) to the total score of 100.
The information provided by the patient on each domain
was used by the physician to judge whether a risk factor of
exposure to FFCm’s associated to this domain was present
or absent and to assign the scores accordingly.
We selected the medicine classes for inclusion in the
watch-list in line with the findings of the preliminary report
[11] which had identified 7 therapeutic classes frequently
seized in Europe as FFC. Amongst them were medicines
with psycho-analeptic, antibiotic, anabolic properties, as
well as medicines to treat cardiovascular diseases, erectile
dysfunction, obesity and various health care products.
Three experts (an endocrinologist, a psychiatrist, and a
pharmacist) prepared the watch-list section „clinical signs“
and the life-style questions included in the questionnaire.
Information regarding the signs associated with the use of
56 individual medicines (brands) belonging to the above 7
therapeutic classes was sourced from literature.
Those 56 individual medicines had been identified as
FFC by the OMCLs. The types and extent of the quality
defects had been confirmed through analytical methods.
The life-style questions (25 in total) addressed behav-
iours and attitudes of patients associated with a risk of
using medicines and health care products to alter body ap-
pearance or performance. The selection of these questions
was based on data regarding patterns of their use [5] and
on the experts’ own clinical experiences and were phrased
in a non-blaming and non-embarrassing style.
All physicians participating in the sub-studies contrib-
uted to the development of the tool and the study pro-
cesses before the beginning of the study in oral and
written communication. (Selection of the participating
physicians, see “Setting and participants”).
The tool, the reference method and the study pro-
cesses were pre-tested in a pilot-study which was
carried out in self-reported users of watch-list-
medicines in an ambulatory care study site (Belgrade,
Serbia).
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Reference method (validation of the tool)
The retrospective assessment of the medical records of all
patients including all diagnostic tests performed after the
initial consultation, in particular biomarkers and clinical
signs or symptoms, response to medical treatment and pro-
gress of disease, was used as the reference method (see Ma-
terials and Processes, Step 3). In order to compile possible
signals (relevant (bio)markers, other clinical findings and
the progress of disease) for the retrospective assessment, a
pilot-study was carried out in a sports clinic (Belgrade,
Serbia) in 105 athletes. They reported use of most classes of
the watch-list-medicines: anabolic agents, anti-obesity prep-
arations, sex hormones and modulators of the genital sys-
tem including medicines for erectile dysfunction, diuretics
and a multitude of healthcare products, and presented
health complaints. Nearly all medicines (90%) were pur-
chased from poorly controlled or uncontrolled outlets and
were possibly falsely labelled, falsified (counterfeit). The tool
was used according to the study processes and the use and
origin of the medicines, relevant (bio)markers, other clinical
findings and the progress of disease was documented and
shared with the participating physicians.
Setting and participants
The study-setting comprised 1 pilot-study and 5 sub-
studies in ambulatory and in-patient care sites in 6 differ-
ent countries in Europe (Table 1). Experts (1) were con-
sulted to select those classes of medicines for the
validation study which were relevant in the respective
country from the perspective of public health protection.
These experts also identified the health care sites and the
participating physicians. Each ambulatory care site was
expected to test the tool in 30 patients using medicines
belonging to the selected class(es) during the 3-months
study period (2013–2014). Each in-patient site was
expected to test the tool in 100 patients.
In general, patients below the age of 14 years and
those aged above 65 years were excluded (Table 1), with
the exception of the sub-study in Yerevan: this study
focused on antibiotic treatment and enrolled patients with
mild to moderate infections, irrespective of their age.
Materials and processes
Electronic files of the tool were provided to the partici-
pating physicians, either complete or limited to the
Table 1 Health care settings, exclusion criteria, patient characteristics, selected medicines classes
Health care setting Exclusion criteria: All
sub-studies: female
patients as regards
erectile dysfunction
medicines(G04BE)
Number: enrolled
(evaluated)
Sex (m/f) Age (Median, Interquartile
range Q1-Q3): all patients;
(m/f)
Medicines classes
(WHO ATC)
Ambulatory Yerevan (Armenia) Patients of all age
groups with mild to
moderate infections
50 24/26 33 (20.5–45.5)
(34 (19–49)/
/31 (19.5–42.5)
Antibiotics (J01)
Ambulatory Zagreb & Pula
(Croatia)
Patients <14, > 65 y; 71 (70)a 34/36 47 (35–59)
(48 (37.7–58.5)/
43.5 (30.5–56.5)
Anti-obesity Preparations,
Excl. Diet Products (A08),
Anabolic Agents for Systemic
Use (A14), Diuretics (C03),
Sex Hormones and Modulators
of the Genital System (G03),
Urologicals (G04),
Psycho-analeptics (N06)
Ambulatory Rome (Italy) Patients <14, > 65 y 60 (60) 60 m m: 32 (25.4–38.6) Anabolic Agents for Systemic
Use, Diuretics, Sex Hormones
and Modulators of the Genital
System, Urologicals
Pilot-study
Ambulatory
Sports out-patient
clinic Belgrade (Serbia)
Patients <14, > 65 y; 105 (105) 79/26 33 (27–39)
(33 (26.5–39.5)/
33 (28–38))
Anti-obesity Preparations,
anabolic agents for systemic
use, Diuretics, Sex Hormones
and Modulators of the Genital
System
In-patient
Aalst (Belgium)
Patients <14, > 65 y; 42 42 23/19 42 (27.4–56.7)
(45 (27.3–53.8)
42 (30–54)
Anti-obesity Preparations, Anabolic
Agents for Systemic Use, Diuretics,
Sex Hormones and Modulators of
the Genital System, Urologicals,
Psycho-analeptics
In-patient Reykjavík (Iceland) Patients <14, > 65 y; 149 (149) 51/98 47 (32.5– 61.5)
(46 (31.5–60.5)/
48 (34–62)
Anti-obesity Preparations
Legend: WHO ATC: Anatomical Therapeutic Chemical Classification of Medicinal Products. Source: World Health Organization
(WHO). (http://www.whocc.no/atc_ddd_index)
aOne (1) patient was excluded due to incomplete documentation
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classes of medicines selected for the respective sub-
study. The participating physicians were trained during
phone conferences, with respect to the study processes,
sensitive questioning and avoidance of pre-selection of
patients by personal judgement. A meeting was held for
the participating physicians after the data lock point to
discuss practical details of the retrospective assessment
of patients’ medical records (see Statistical analysis).
The study processes comprised 3 steps:
Step 1: The physician included the questionnaire in the
questioning of the patient at the first consultation
and scored the information using the watch-list. The
physician established whether harm caused by
FFCm’s was “probable” requiring the presence of at
least 2 of 5 risk indicators (corresponding to ≥ 40
scores), or “unlikely”.
Step 2: The therapy and further diagnostic
interventions were carried out in line with the site’s
usual protocols.
Step 3: After the patient had been discharged from
in-patient care or after alleviation of symptoms
(ambulatory care), the physician assessed the
patient’s medical record, regarding
 all diagnostic tests performed after the initial
consultation, in particular biomarkers and clinical
signs or symptoms,
 response to medical treatment,
 progress of disease.
In the sub-study focusing on FFC antibiotics, consecu-
tive antibiograms were assessed in accordance with med-
ical guidelines.
The physician documented on the scoring form
whether the above findings maintained the initial risk
status („true positive” or “true negative”) or provided
grounds for rejection (“false positive” or “false negative”).
Statistical analysis
Standard descriptive statistics were used to analyse count
variables and continuous variables (Tables 1 and 2).
The results from the pilot-study in patients self-
reported users of watch-list medicines (Belgrade, Serbia)
were not included in the statistical analysis of the
discrimination power of the tool, because the patients’
risk status was known. (See Methods: Reference method
(validation of the tool).
Correctly and falsely classified patients (absolute frequen-
cies) were stratified into ambulatory and in-patient care sites
and for each individual sub-study. The tool’s power to dis-
criminate between patients harmed by FFCm’s and those
who were not harmed was evaluated with respect to “sensi-
tivity” and “specificity”, likelihood ratios, and predictive
values (see legend Table 2). The sensitivity and specificity of
the tool was expressed as “exact two-sided 95% confidence
intervals” according to the method of Clopper and Pearson
[13–15] (Table 2) for 2 and for 3 of 5 risk indicators in order
to establish a discrimination threshold (“cut-off level”) which
correctly classifies cases of harm at a minimum of false clas-
sifications.3 The post-test probability was estimated using
Fagan’s Nomogram for Bayes’s Theorem [16] adapted for
interpreting diagnostic results, based on estimates of preva-
lence of health care system contamination with FFCm’s and
of users of non-prescribed medicines from uncontrolled out-
lets, often FFC. The implications of setting a cut-off level
(≥40 or ≥ 60 of 100 scores corresponding to the presence of
2 or 3 risk factors, respectively) on the discrimination power
of the tool are addressed in the discussion.
Added value (convenience of use) of the tool to physi-
cians: The participating physicians provided their
perception via a questionnaire with open-ended ques-
tions upon completion of the sub-study. Their views
were analysed in a qualitative manner by clustering them
according to topic and emphasis (See Table 3).
Results
Discrimination power
Sensitivity, specificity, likelihood ratios of all sub-studies (in
the presence of 2 or 3 of 5 risk factors) are listed in Table 2.
Ambulatory care setting sub-studies
Yerevan (Armenia)
Fifty patients with mild to moderate infection of different
aetiology presented in the general practitioner’s office. One
of the 11 cases scoring above 40 scores, corresponding to
the presence of 2 of 5 risk factors, was maintained as true
positive: urinary infection by Staphylococcus aureus had
been confirmed through an antibiogram. Rocephin®
(ceftriaxone) was administered for 7 days (1 g/day). A
subsequent antibiogram showed continued presence of the
microorganisms and sensitivity to ceftriaxone. Second line
treatment, rovamycine, was successful. The third
microbiological analysis demonstrated that Staphylococcus
aureus was no longer present.
Additionally, the tool helped find 3 patients who
reported use of “biologically active supplements” to
improve their performance in sports. As supplements
advertised as “biologically active” are known to contain
hormones for muscle growth, patients could be coun-
selled during the consultation about the health risk
associated with the use of those products.
Zagreb and Pula (Croatia)
Seventy one patients attended two offices of the same gen-
eral practitioners’ network for non-serious ailments and
chronic diseases. One of the 21 cases scoring above 40
scores corresponding to the presence of 2 of 5 risk factors,
was maintained as true positive: the patient presented with
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Table 2 Discrimination power of the tool
Health care setting/Medicines True positivesa (n) False positivesb (n) Cut-off level (scores) of 100: Sensitivity/Specificity
(%) (Confidence intervalsc: Lower 95% CL; Upper
95% CL); Positive/Negatived Likelihood ratios (LR+/LR-)
Ambulatory Yerevan (Armenia)/Antibiotics 1 10 ≥40:
Sensitivity 100 (2.5 100)
Specificity 79.95 (65.66 89.76)
LR+ 4.9
LR- 0
0 2 ≥60
Sensitivity NaN (0 100)
Specificity 96 (86.29 99.51)
LR+ N/A
LR- NaN
Ambulatory Zagreb & Pula (Croatia)/
Anti-obesity Preparations, Anabolic
Agents for Systemic use, Diuretics,
Sex Hormones and Modulators of the
Genital System, Urologicals, Psycho-analeptics
1 20 ≥40
Sensitivity 100 (2.5 100)
Specificity 71.01 (58.84 81.31)
LR+ 3.5
LR- 0
1 13 ≥60
Sensitivity 100 (2.5 100)
Specificity 81.16 (69.94 89.57)
LR+ 5.3
LR- 0
Ambulatory Rome (Italy)/
Anabolic Agents for Systemic use,
Diuretics, Sex Hormones and Modulators
of the Genital System, Urologicals
3 0 ≥40; ≥60
Sensitivity 100 (29.24 100)
Specificity 100 (93.73 100)
LR+ -
LR- 0
All ambulatory sub-studies
Yerevan (Armenia), Zagreb & Pula
(Croatia), Rome (Italy)
5 30 ≥40
Sensitivity 100 (47.82 100)
Specificity 82.86 (76.44 88.12)
LR+ 5.8
LR- 0
Ambulatory sub-studies
Yerevan (Armenia), Zagreb & Pula
(Croatia), Rome (Italy)
≥40
Sensitivity 100 (39.76 100)
Specificity 84.13 (76.56 90.03)
LR+ 6.3
LR- 0
≥60
Sensitivity 100 (39.76 100)
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increased levels of hepatic enzymes for more than 3 days, a
sign of hepatic disorder, and was therefore referred to the
hospital. At the initial consultation, the patient had reported
the use of a dietary supplement. The hospital’s discharge re-
port confirmed hepatic disorder due to the use of a product
containing the anabolic agent oxandrolone.
Rome (Italy)
Sixty patients with non-serious health complaints pre-
sented at the offices of a general practitioners’ network.
15% of the patients reported practising sport, one
professionally, the others for leisure.
Three patients with cardiovascular symptoms (ele-
vated blood pressure, wheezing, dizziness, and
arrhythmia) scored above 40 scores corresponding to
the presence of 2 of 5 risk factors. These 3 patients de-
nied practising sport. One of them reported using sil-
denafil, a medicine to treat erectile dysfunction. At the
initial consultation, none of them reported use of
other medicines, vitamins and amino acids (health
care products). Further medical examination estab-
lished disease (cardiopathies) and altered hepatic
enzyme profile and testosteronaemia.
In the course of subsequent treatment it was con-
firmed that the patients had used the anabolic agents
Table 2 Discrimination power of the tool (Continued)
Health care setting/Medicines True positivesa (n) False positivesb (n) Cut-off level (scores) of 100: Sensitivity/Specificity
(%) (Confidence intervalsc: Lower 95% CL; Upper
95% CL); Positive/Negatived Likelihood ratios (LR+/LR-)
Specificity 89.68 (83 94.39)
LR+ 9.7
LR- 0
In-patient Aalst (Belgium)/Anti-obesity
Preparations, Anabolic Agents for
Systemic Use, Diuretics, Sex Hormones
and Modulators of the Genital System;
Urologicals, Psychoanaleptics
0 33 ≥40
Sensitivity 0 100
Specificity 21.43 (10.3 36.81)
LR+ N/A
LR-
0 11 ≥60
Sensitivity 0 100
Specificity 73.81 (57.96 86.14)
LR+ N/A
LR
In-patient Reykjavík (Iceland)/
Anti-obesity Preparations
0 13 ≥40
Sensitivity 0 100
Specificity 92.52 (87.01 96.21)
LR+ N/A
LR-
0 5 ≥60
Sensitivity 0 100
Specificity 96.64 (92.34 98.9)
LR+ N/A
LR-
Legend
The cut-off level which classified correctly the cases of harm at a minimum of false classifications is highlighted in bold letters
a“True positive”: The initial classification of the patient by the tool as “probably being at risk of health damage caused by FFC medicines” was maintained after the
retrospective assessment of the medical record (“reference method”)
b“False positive”: The initial classification of the patient by the tool as probably being at risk of health damage caused by FFC medicines” was rejected after the
retrospective assessment of the medical records (“reference method”)
cThe sensitivity and specificity of the tool were expressed as “exact two-sided 95% confidence intervals” according to the method of Clopper and Pearson for the
presence of 2 and 3 of 5 risk indicators
dPositive/negative likelihood ratios: the ability of a test to discriminate between people likely to have a disorder and those less likely to have a disorder is
determined by the test’s likelihood ratio (LR)
The ratio of true positives to false positives (LR+) is the likelihood ratio for a positive test result being correct
The ratio of false negatives to true negatives (LR-) is the likelihood ratio for a negative test result being correct
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for systemic use: nandrolone decanoate, testosterone
enanthate, mesterolone, boldenone undecyclenate,
trenbolone hexahydro-benzylcarbonate, testosterone
propionate and stanazolol.
In the whole patient group, the use of vitamins and
dietary supplements (protein-amino acid vitamin mix,
creatin mix, “Thermoburner Animals stack mix”) was
common: 25 patients reported use of supplements
upon the recommendation of “…fitness-trainers,
friends, family members or physicians…”.
In-patient setting sub-studies
Aalst (Belgium)
Fourty two patients admitted to the emergency unit
presented with pain due to traumatic injury or in-
ternal or psychiatric diseases. 33 patients scoring
above 40 scores corresponding to the presence of 2
of 5 risk factors, were not maintained (they were
falsely classified as positive). They did not report use
of medicines or health care products included in the
watch-list.
Table 3 Added value (convenience of use) of the tool
Health care setting Participating physicians’ views
Ambulatory
Yerevan (Armenia)
“…The approach proved suitable for use in case of unavoidable exposure to FFCm’s
contaminating the legal chain for example essential medicines (antibiotics)… and
deliberate purchases from uncontrolled sources …”.
Ambulatory
Zagreb& Pula (Croatia)
“…Systematic approach for the identification of risk factors… it justifies the
consideration of alternative diagnosis; opportunity for counselling of patient
(preventative role)....
…additional anamnestic questions increased the duration of the consultation on
average 6. 2 min (range: 3. 2- 11.4 min).
However this time should not be considered a mere prolongation of the consultation:
it helps establish the suspicion of possible “poisoning” which by itself has to be
clarified thoroughly.
Physicians have an inherent and professional interest to understand the nature of
the observed symptom. Our questionnaire only helps do that. ”
Ambulatory
Rome (Italy)
“…The decision aid is useful to find patients at risk, combining known risk factors with
the medical history of individual patients; but also offering alternatives for possible
diagnosis (“differential diagnosis options”) to document and justify further diagnostic
interventions....
The present observational study, though small, showed the existence of unsafe use
of medicines (like phosphor-diesterase inhibitors), consumption of psychoactive
substances and substances with a doping effect, as well as the indiscriminate use of
dietary supplements which possibly cause disabling symptoms and a medical referral.
…We can say that the protocol adopted here is potentially useful to define not only
the characteristics of subjects potentially at risk for the use and abuse of medicines
in the differential diagnosis of a condition possibly iatrogenic but also useful to
identify with greater specificity the need for further investigation diagnostics.
The use of the decision aid requires 20–30 min.
It is most important is that the physician does not question the patient in a ”sterile
manner“ but tries to understand personal motivation (problems) through direct
and indirect questions ….”.
Pilot-study
Ambulatory
Belgrade (Serbia)
“…Health care settings with easy access (primary care) and mid to long- term trusted
relationship are suitable…”
…Welcome the decision aid: this is, for the first time, a tool set up specifically for
doctors. The primary care sector, such as family doctors, who are easy to access and
have usually a longer-term, trusted relation with the patients, is well positioned to
find patients at high risk of health damage by medicines produced and distributed
outside the legal chain such as counterfeit (falsified) medicinal products…..
…In consultations, time is limited: risk status output needs to be integrated into
patients’ questioning (anamnesis)…”.
In-patient Aalst (Belgium) “….The decision aid gives an important reminder to the doctor – to take into account
in treatment decisions and risk prevention, adverse reactions caused by FFC products;
it could be a useful complement ….
…Manual scoring (used in this observational study setting) is impractical in real-life
situation…..”
In-patient Reykjavík (Iceland) “…There is no doubt that the topic of this project is very important. In my opinion
it is more important that doctors always bear this in mind and include questions on
the use of alternative medicines and/or counterfeit medicines. The consultation tool
does not seem to be cost effective for use in unselected patients presenting in a
general practice or in a gastroenterology clinic.
…Biomarkers (of health damage caused by FFC products) are needed …”.
Legend: The participating physicians provided their views (perception) of the added value and the convenience of use of the tool via a questionnaire with
open-ended questions
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The assessment of the medical records identified
severe traumatic injury, internal or psychiatric diseases
as causal of the symptoms.
Reykjavík (Iceland)
One hundred fourty nine patients presented with gastro-
enterological symptoms, pain, and mood alterations
(psychiatric symptoms) at the internal medicine depart-
ment. 13 patients scoring above the cut-off level of 40
scores corresponding to the presence of 2 of 5 risk
factors, were classified retrospectively as false positive:
Among these patients, were 4 patients who had reported
the use of watch-list-medicines and healthcare products:
one patient had used a product stimulating the thyroid
gland with no relevant medical history, and the other 3
patients had used herbal products. The retrospective
assessment of the medical records of those 4 patients
suggested anaemia in 2 patients, Wilson’s (hepatic)
disease in 1 patient, and gastro-intestinal tract disorder
in 1 patient as causal of their health complaints.
The frequencies of health complaints, usage of medicines
and health care products before consultation, and medical
history are included in (Additional file 2: Table S1): In
summary, patients’ medical history and health complaints
were consistent with the reported medicines’ usage.
Added value (convenience of use)
The participating physicians from all sub-studies, includ-
ing the pilot-study, gave their views on the “added value”
and “convenience of use” of the tool (Table 3). In
general, the physicians perceived the tool as a valuable
element of patient questioning during consultations, as
there was consensus that the prevention of health dam-
age caused by FFCm’s is important.
One physician (Zagreb, Croatia) estimated that the time
needed to complete the questionnaire during consultations
took on average about 6 min (from 3. 2 to 11. 4 min).
The physicians considered the ambulatory care setting
as “well-placed” to find patients harmed by FFCm’s and
to carry out effective patient counselling, particularly, if
there was a long-standing and trusted patient-doctor re-
lationship. They were of the opinion that patients would
often hesitate to answer straight-forward questions re-
garding the use and origin of medicines and health care
products for life-style purposes (weight-loss, beauty,
sports) or sexual performance: therefore, sensitive life-
style questioning, as supported by the tool, is most
suitable for obtaining information. The physicians par-
ticipating in the in-patient care sub-studies considered
the tool as not being cost-effective in a sample of “non-
selected” patients, in particular if the occurrence of
FFCm’s was low. They recognised, however, the practical
value of the tool as an “aide memoire” about types and
clinical symptoms caused by FFCm’s.
All physicians considered manual scoring as required
by this preliminary version of the tool as too time-
consuming for medical practice.
Discussion
The discussion of the implications of the study results with
regard to the study aims requires a rather detailed analysis.
Discrimination power of the tool
Ambulatory care: One sub-study focused on essential
medicines (antibiotics) in Yerevan, Armenia, a region
where the estimated level of contamination of the health
care system with FFC medicines is 10-20% [17]. The
incidence of counterfeit Rocephin® in Armenia before
and during the study period had been confirmed by the
competent authorities. It is therefore plausible that one
patient (out of 50 patients using more than one medi-
cinal product at a time) was classified correctly as “prob-
ably” harmed by a FFC antibiotic. This case was
identified at a cut-off level of ≥ 40 scores corresponding
to the presence of 2 of 5 risk factors.
Although the LR+ 4.9/LR- 0 generates only a moderate
effectiveness in diagnosing if a patient is harmed by
FFCm’s, it moves the post-test probability to about 35 –
60% for an estimated level of health care system contam-
ination of 10 – 20% with FFCm’s (prevalence). Increas-
ing the cut-off level to 3 of 5 risk factors (≥60 scores)
would have missed the case. This may in similar cases
put patients at risk of undertreatment of their infection
and contribute to the development of bacterial resist-
ance. Furthermore, the early detection of the FFC anti-
biotic and replacement by a genuine medicine could, in
similar cases, render unnecessary a switch to second line
antibiotics which are often more toxic.
In contrast to low-income countries with wide-spread
health care system contamination with FFCm’s exposing a
considerable proportion of the population to FFCm’s, the
contamination of the health care system is very low (<1%)
in Middle-Europe. However, a considerable number of in-
dividuals are purchasing medicines without the required
prescription, e.g. for erectile dysfunction or anabolic
agents, or health care products for life-style purposes
(slimming and beauty) from non-regulated outlets, such
as the internet. This could be risky as 50% of the medi-
cines distributed via internet sites which do not reveal
their identity are probably falsified [17]. The two sub-
studies in Rome (Italy) and Zagreb and Pula (Croatia)
focused on the risk of health damage caused by FFC prod-
ucts purchased from uncontrolled outlets in the setting of
the offices of a general practitioners’ network.
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In these 2 sub-studies, four out of 130 patients (3%) were
correctly classified as probably harmed by FFC medicines
or products. This is plausible in the light of an EU Commis-
sion study (2002) [18] which revealed that, on average, 5%
of fitness centre clients, including school children and stu-
dents, in the four member states concerned (Belgium,
Germany, Italy, Portugal) reported the regular use of ana-
bolic steroids, diuretics, stimulants, food supplements and
anti-oestrogens. A cut-off level of ≥ 40 scores corresponding
to the presence of 2 of 5 risk factors classifies correctly the
cases of harm but results in elevated numbers of false clas-
sifications. Moving the cut-off level from ≥ 40 scores to ≥ 60
scores in the above 2 sub-studies reduces the number of
false positives from 20 to 13 and maintains the number of 4
correctly classified cases. Therefore, we think that a cut-off
level of ≥ 60 scores, corresponding to the presence of 3 risk
factors of 5 risk factors, including the impact of life-style
choices, is more proportionate to a scenario where FFCm’s
are purchased by individuals via un-controlled outlets and
can augment the usefulness of the tool in this setting. The
resulting LR+ 9.7/LR- 0 can generate a moderate to larger
effectiveness in diagnosing if a patient is harmed by FFCm’s
or health products, moving the post-test probability to about
33% in this specific population group at risk (5% prevalence
of use of non-prescribed medicines in fitness club clients).
The relevance to public health is illustrated by the
following data: In Italy, 32% of all fitness centre clients
are aged between 18–25 years [19], the age group which
most intensely practises body-building. In 2014, 6 074
293 persons (9, 8% of the population) [20] were aged
between 15–24 years.
In-patient care: In one hundred and ninety one patients,
no patient was classified correctly as harmed by watch-list-
medicines and health care products. We assume that in this
sample of patients, who suffered either from traumatic injury
and severe internal or psychiatric diseases, patients harmed
by FFCm’s were under-represented. This may particularly
apply to the patients enrolled in the sub-study in Reykjavík,
which focused on health damage caused by one medicine
class, FFC anti-obesity preparations. Given the small popula-
tion size of Iceland and the relatively short study period, it is
probable that patients harmed by FFC slimming products
were not represented.
Added value (convenience of use) of the tool
Our study aimed at a “proof of principle” of the tool
and did not carry out a cost/benefit calculation for
the use of the tool.
The participating physicians considered the use of the
questionnaire as time-effective support to patient questioning
during consultation. In particular, they welcomed the devel-
opment of the specific watch-list combining the main factors
that influence the extent of health damage caused by FFCm’s
in an individual patient presenting clinical signs associated
with the use of FFCm’s. The tool provides for sensitive and
empathic questioning which is particularly important when
addressing topics such as erectile dysfunction, slimming and
use of performance enhancing products in sports. Experience
shows that many patients will not speak openly when asked
directly by a doctor about the products they took and where
they had purchased them. The study results suggest that the
tool can support the physician in carrying out a comprehen-
sive patient questioning during consultation, including risk
factors of harm caused by FFCm’s.
In order to solve the issues with time-consuming manual
scoring and searching the watch-list raised by the physicians,
common table calculation software could be used as a first
step to digitalise the tool.
Systematic and continuous communication between the
health authorities and the medical and health profes-
sionals’ community concerning new types and quality de-
fects of FFCm’s and illegal healthcare products, patterns
of their use and clinical signs and symptoms of associated
health damage are needed to foster the sustainable and ef-
fective implementation of the tool in practice. Regular
systematic updates and follow-up with the medical com-
munity are important to build and maintain a “pool” of
expertise and motivation. Both aspects are part of the
development concept and the design of the tool which
permits easy modification, as necessary. Further research
is recommended on the digitalisation of the tool, bio-
markers and possible uses of the tool to promote the
awareness of physicians of FFCm’s.
Study strengths and limitations
A strict procedure was followed in order to minimise a
possible “expectation bias” which could have distorted the
results of the retrospective assessment (reference method).
The physician, coordinator of the pilot-study (Belgrade,
Serbia), reviewed the retrospective assessment of all
medical records and the patient data after the completion
of the whole study and compiled the study data. This
physician was not involved in scoring the patients of the
sub-studies or in the subsequent treatment.
It is a study limitation that samples of the medicines
were not available for analysis and no technically sophis-
ticated diagnostic analyses were carried out. Although
such methods could be considered a “gold standard”,
validated chemical-analytical methods are not always
available and their use would limit the wide-spread use
of the tool under “real-life” conditions.
In line with published data [21], we assumed that
medicines produced and distributed illegally (e.g. “black
market”, illegal internet sites) were substandard or FFC.
The results obtained in the sub-studies in Rome and
Zagreb & Pula suggest that the tool is of added value in
regions with a higher representation of specific risk
groups, such as fitness club clients with an estimated
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prevalence of 5% users of non-prescribed medicines/
health care products: 4 cases correctly classified in this
setting equals 3% of the enrolled patients. It may be of
significance that the offices of the general practitioners’
network (Rome) were located in the vicinity of fitness
centres and military barracks.
The retrospective assessment of the medical records
did not reveal harm by FFCm’s which was missed by the
initial scoring (there were no “false negatives”). Several
reasons may account for this observation:
 short observation time,
 prevalence of FFCm contamination in the study
sample lower than assumed, perhaps due to selective
use of brands or classes of medicines by the
respective health care sites,
 large dose variability among individual units and
batches of FFCm’s as demonstrated by Venhuis et al.
(2013) [22] who concluded: “…In the worst case,
counterfeit or unauthorised medicines are not
recognised as such or health risk is not identified
giving rise to ”false negative“ results…”.
Conclusions
We consider this “decision aid” a systematic tool for physi-
cians to find in medical practice patients harmed by FFCm’s.
The tool can be integrated into routine patient questioning,
diagnosis and treatment planning. The structure (question-
naire, watch-list, scoring forms) permits easy updates as
new information becomes available. However, for being im-
plemented in practice, scoring and searching the watch-list
should be made more practical and less time-consuming.
This would require digitalisation. The tool could be particu-
larly useful in the ambulatory care setting in regions with a
level of 10–20% contamination of the health care system by
FFCm’s or in specific population groups at elevated risk of
FFCm’s and health care products from uncontrolled outlets.
Regular communication, systematic updates between the
health authorities and the medical community are important
to build and maintain a “pool” of expertise and knowledge
and to foster motivation. Both aspects are part of the con-
cept and operationalised tool. These principles are a corner-
stone of a successful application of the tool, acceptance by
physicians, and may contribute to find and reduce health
damage caused by FFCm’s. Further development could focus
on the digitalisation of the tool, the inclusion of suitable bio-
markers of harm and on possible uses of the tool in training
or as “aide memoire” to raise the awareness of physicians of
FFCm’s and associated health damage.
Endnotes
1The EDQM coordinates the work programme carried
out by the Council of Europe Committee of Experts on
Minimising Public Health Risks posed by Counterfeiting
of Medical Products and Similar Crimes (CD-P-CMED).
The experts represent national authorities.
2The national OMCLs are important partners of the
competent authorities as regards the detection of
FFCm’s on the markets and the analytical determination
of quality defects. Networking among OMCLs in Europe
is supported via the European Network of Official
Control Laboratories coordinated by the EDQM [12].
3The “Clopper/Pearson” Calculator [14] did not calcu-
late confidence intervals for the likelihood ratios (LR
+/LR-).
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